Monitor upcoming preclinical data presentations and Phase I safety/dose escalation results, which could serve as catalysts. This trial expands HUTCHMED’s ATTC platform validation but is too early to impact near-term valuation.
HCM drugs
HCM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 4 $13.65entry
- T+1 · 9mo ago +1.50%α +2.08% · $13.85
- T+5 · 8mo ago +6.78%α +8.11% · $14.57
- T+20 · 8mo ago +10.96%α +15.37% · $15.14
- T+60 · 6mo ago −17.70%α −27.79% · $11.23
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HUTCHMED has initiated a Phase I/IIa clinical trial for HMPL-A580, its second Antibody-Targeted Therapy Conjugate (ATTC), in patients with advanced solid tumors in both China and the US. The first patient was dosed on March 4, 2026, marking a key step in the development of this first-in-class therapy targeting the PAM pathway and EGFR signaling.
Key Facts
- HUTCHMED initiated a Phase I/IIa trial for HMPL-A580, its second ATTC candidate, on March 4, 2026.
- The trial is ongoing in the US and China and is first-in-human, evaluating safety, pharmacokinetics, and preliminary efficacy.
- HMPL-A580 combines a novel PI3K/PIKK inhibitor payload with an anti-EGFR antibody to target EGFR-expressing solid tumors.
- Preclinical data suggest synergistic activity between PAM pathway inhibition and EGFR blockade.
- Trial details are available at clinicaltrials.gov under NCT07396584.
Financial Impact
No immediate financial impact; early-stage trial with potential long-term value if clinical success is achieved
Risk Factors
- High risk typical of early-phase clinical development; safety or tolerability issues could halt development.
- Limited near-term commercial visibility; multi-year timeline to potential approval, if successful.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249083 |
Track record
33 reports on HCM
8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 18 of 23 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers